HK1169388A1 - 6,7,8,9-tetrahydro-pyrimido1,2-a pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof 6789-12-a -4- - Google Patents

6,7,8,9-tetrahydro-pyrimido1,2-a pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof 6789-12-a -4-

Info

Publication number
HK1169388A1
HK1169388A1 HK12109830.1A HK12109830A HK1169388A1 HK 1169388 A1 HK1169388 A1 HK 1169388A1 HK 12109830 A HK12109830 A HK 12109830A HK 1169388 A1 HK1169388 A1 HK 1169388A1
Authority
HK
Hong Kong
Prior art keywords
pyrimido1
pyrimidin
tetrahydro
derivatives
preparation
Prior art date
Application number
HK12109830.1A
Other languages
English (en)
Chinese (zh)
Inventor
Eric Bacque
Maurice Brollo
Annie Clauss
Ahmad Youssef El
Bruno Filoche-Romm
Frank Halley
Karl Andreas Karlsson
Gilbert Marciniak
Baptiste Ronan
Laurent Schio
Bertrand Vivet
Fabrice Viviani
Andr Zimmermann
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0903237A external-priority patent/FR2947551B1/fr
Priority claimed from FR0957069A external-priority patent/FR2951174B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HK1169388A1 publication Critical patent/HK1169388A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK12109830.1A 2009-07-02 2012-10-08 6,7,8,9-tetrahydro-pyrimido1,2-a pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof 6789-12-a -4- HK1169388A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0903237A FR2947551B1 (fr) 2009-07-02 2009-07-02 Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
US24109809P 2009-09-10 2009-09-10
FR0957069A FR2951174B1 (fr) 2009-10-09 2009-10-09 Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
PCT/FR2010/051374 WO2011001113A2 (fr) 2009-07-02 2010-07-01 NOUVEAUX DERIVES DE 1,2,3,4-TETRAHYDRO-PYRIMIDO{1,2-a}PYRIMIDIN-6-ONE,LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE

Publications (1)

Publication Number Publication Date
HK1169388A1 true HK1169388A1 (en) 2013-01-25

Family

ID=43234240

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12109830.1A HK1169388A1 (en) 2009-07-02 2012-10-08 6,7,8,9-tetrahydro-pyrimido1,2-a pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof 6789-12-a -4-

Country Status (24)

Country Link
US (1) US8846670B2 (ja)
EP (1) EP2448940B1 (ja)
JP (1) JP5655070B2 (ja)
KR (1) KR20120103553A (ja)
CN (1) CN102482286B (ja)
AR (1) AR077363A1 (ja)
AU (1) AU2010267815B2 (ja)
BR (1) BRPI1015943A8 (ja)
CA (1) CA2766909C (ja)
DK (1) DK2448940T3 (ja)
ES (1) ES2487623T3 (ja)
HK (1) HK1169388A1 (ja)
HR (1) HRP20140786T1 (ja)
IL (1) IL217293A (ja)
MX (1) MX2012000103A (ja)
MY (1) MY155661A (ja)
PL (1) PL2448940T3 (ja)
PT (1) PT2448940E (ja)
RU (1) RU2561130C2 (ja)
SG (2) SG177464A1 (ja)
SI (1) SI2448940T1 (ja)
TW (1) TWI455940B (ja)
UY (1) UY32754A (ja)
WO (1) WO2011001113A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2655375T3 (pl) 2010-12-23 2015-05-29 Sanofi Sa Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie
FR2969613B1 (fr) * 2010-12-23 2013-02-08 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique
DK2790705T3 (en) 2011-12-15 2018-03-12 Novartis Ag Use of inhibitors of the activity or function of PI3K
FR2992316A1 (fr) * 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr) * 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
EP3828269B1 (en) 2015-03-06 2023-05-03 Korea Advanced Institute Of Science And Technology Composition for prevention or treatment of intractable epilepsy comprising mtor inhibitor
PL3416957T3 (pl) 2016-02-19 2021-02-08 Sprint Bioscience Ab Związki 6-heterocyklilo-4-morfolino-4-ylopirydyn-2-onu przydatne w leczeniu raka i cukrzycy
LT3416945T (lt) 2016-02-19 2020-11-25 Sprint Bioscience Ab 6-aril-4-(morfolin-4-il)-1h-piridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui
JP2023515708A (ja) * 2020-04-27 2023-04-13 アルナ バイオ， インコーポレーテッド 中枢神経系送達のための結合剤及びその使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2703712A1 (de) * 1977-01-29 1978-08-03 Bayer Ag Substituierte pyrimidinon eckige klammer auf (di)-thio eckige klammer zu -phosphor-(phosphon)-saeureester bzw. -esteramide, verfahren zu ihrer herstellung und ihre verwendung als insektizide, akarizide und nematizide
MY125533A (en) * 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
PT1257537E (pt) 2000-01-24 2007-08-03 Astrazeneca Ab Compostos terapêuticos morfolino-substituídos.
WO2002018386A1 (en) * 2000-09-01 2002-03-07 Sanofi-Synthelabo 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATI VES
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
EP1340761A1 (en) 2002-02-28 2003-09-03 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
MXPA04002629A (es) 2001-09-21 2005-02-17 Sanofi Aventis Derivados de 2-piridinil-6, 7, 8, 9-tetrahidropirimido [1, 2-a] pirimidin-4-ona y 7-piridinil-2, 3-dihidroimidazo [1, 2-a] pirimidin-5(1h) -ona.
BR0308109A (pt) * 2002-02-28 2005-01-04 Sanofi Aventis Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila
US7598377B2 (en) 2002-08-16 2009-10-06 Astrazeneca Ab Inhibition of phosphoinositide 3-kinase β
AU2003292436B2 (en) * 2002-12-27 2009-07-30 Msd Italia S.R.L. Tetrahydro-4H-pyrido[1,2-A]pyrimidines and related compounds useful as HIV integrase inhibitors
EP1454909B1 (en) 2003-03-07 2008-08-20 Sanofi Aventis 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases
EP1460076A1 (en) 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
EP1557417B1 (en) 2003-12-19 2007-03-07 Sanofi-Aventis Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives
AR054438A1 (es) * 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
EP1895997A2 (en) 2005-05-26 2008-03-12 Kudos Pharmaceuticals Ltd Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
WO2008148074A2 (en) * 2007-05-24 2008-12-04 Research Foundation Of State University Of New York Inhibitors of mtor and methods of treatment using same

Also Published As

Publication number Publication date
EP2448940B1 (fr) 2014-05-21
UY32754A (es) 2011-01-31
IL217293A0 (en) 2012-02-29
AU2010267815B2 (en) 2015-07-16
WO2011001113A2 (fr) 2011-01-06
RU2561130C2 (ru) 2015-08-20
RU2012103477A (ru) 2013-08-10
SI2448940T1 (sl) 2014-10-30
TWI455940B (zh) 2014-10-11
AU2010267815A1 (en) 2012-02-16
US20120208810A1 (en) 2012-08-16
MX2012000103A (es) 2012-05-22
JP2012531463A (ja) 2012-12-10
BRPI1015943A8 (pt) 2018-01-09
EP2448940A2 (fr) 2012-05-09
CA2766909A1 (fr) 2011-01-06
SG10201403149YA (en) 2014-08-28
HRP20140786T1 (hr) 2014-11-07
BRPI1015943A2 (pt) 2016-04-19
WO2011001113A3 (fr) 2011-02-24
PT2448940E (pt) 2014-09-03
CN102482286B (zh) 2015-07-15
KR20120103553A (ko) 2012-09-19
CN102482286A (zh) 2012-05-30
DK2448940T3 (da) 2014-08-25
SG177464A1 (en) 2012-02-28
CA2766909C (fr) 2018-06-05
US8846670B2 (en) 2014-09-30
JP5655070B2 (ja) 2015-01-14
MY155661A (en) 2015-11-13
ES2487623T3 (es) 2014-08-22
TW201105673A (en) 2011-02-16
AR077363A1 (es) 2011-08-24
PL2448940T3 (pl) 2014-10-31
IL217293A (en) 2016-12-29

Similar Documents

Publication Publication Date Title
IL213993A (en) History of 4,3,2,1-tetrahydropyrido [3,2-b] pyrazine-2-one and pharmaceutical preparations containing them
HK1169388A1 (en) 6,7,8,9-tetrahydro-pyrimido1,2-a pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof 6789-12-a -4-
SI2069342T1 (sl) Derivati aril fenil imidazo a piridinov njihova priprava in njihova terapevtska uporaba
IL215911A (en) 7-aryl-1,2,4-triazolo [3,4- a] derivatives, pharmaceutical preparations containing them and methods of preparation and uses thereof
IL215644A (en) N-phenylsulfonyl-2- (h1-pyrrolo [3,2- b] pyridine-5-yloxy) benzamide and anticancer drugs containing them
IL201471A0 (en) Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
IL218490A (en) Oxazolopyrimidinones dihydro hydroxybencyalkyloxymethyl are converted, preparations containing them and their use in the preparation of pharmaceutical preparations
IL220432A (en) History of theo [b – 3,2] pyridinedione and pharmaceutical preparations containing them
SI2655375T1 (sl) Derivati pirimidinona, njihova priprava in njihova farmacevtska uporaba
IL201450A0 (en) Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
SG10201403138WA (en) Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof and pharmaceutical use thereof
IL207972A (en) History of pyridine-2-ram, pharmaceuticals containing them and their use in the preparation of medicines
IL206673A0 (en) Imidazo[1,2-a]pyridine-2-carboxamide derivatives, their preparation and their therapeutic application
IL212942A (en) History of Rifamycin, Methods of Preparation, Pharmaceutical Preparations Containing Them and Their Uses
IL210377A (en) History of Naphthyridone, their preparation and their pharmaceutical preparations
IL206671A0 (en) N-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
SI2588480T1 (sl) Derivati 3,4-dihidropirolo(1,2-a)pirazina-2,8(1H)-dikarboksamida, njihova priprava in terapevtska uporaba
IL220448A (en) Pyridine [3,2 - d] Pyrimidine - 7 (8h) - Their medical uses and uses
IL213588A0 (en) Naphthyridine derivatives, their preparation and pharmaceutical compositions containing them
EP2578586A4 (en) HEXAHYDROPYRROLO [3,4-B] PYRROLE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF
IL206669A0 (en) 6-HETEROCYCLIC IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
TWI366566B (en) Tricyclic n-heteroarylcarboxamide derivatives, preparation thereof and therapeutic use thereof
PL2477990T3 (pl) Pochodne 5-fenylopirazolopirydyny, ich wytwarzanie oraz ich zastosowanie terapeutyczne
IL206672A0 (en) N-HETEROCYCLIC-6-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180701